Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.83 USD
+0.04 (4.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $0.82 -0.01 (-0.62%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.83 USD
+0.04 (4.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $0.82 -0.01 (-0.62%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
Sangamo Therapeutics Initiates Dosing in Hemophilia A Study
by Zacks Equity Research
Sangamo Therapeutics (SGMO) and partner Pfizer announced the dosing of first patient in Alta study on Hemophilia A candidate, SB-525.
What You See, and What You Get: The Neurology of Perception
by Kevin Cook
While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.
Will Sangamo Therapeutics (SGMO) Crush Estimates at Its Next Earnings Report?
by Zacks Equity Research
Sangamo Therapeutics (SGMO) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
3 Biotech Stocks That More than Doubled Year to Date
by Arpita Dutt
Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.
Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.
by Zacks Equity Research
Pfizer Inc. (PFE) has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy (TTR-CM).
Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day
3 Hot Biotech Stocks to Buy in June
by Arpita Dutt
While drug pricing will remain a headline risk, here are a few biotech stocks that have performed well YTD and look well-positioned.
Will Sangamo Therapeutics (SGMO) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Sangamo Therapeutics Inc (SGMO).
Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status
by Zacks Equity Research
Sangamo Therapeutics, Inc. (SGMO) announced that the FDA has granted fast track designation to pipeline candidate, SB-525.
Is the Options Market Predicting a Spike in Sangamo Therapeutics (SGMO) Stock?
by Zacks Equity Research
Investors in Sangamo Therapeuticsm, Inc. (SGMO) need to pay close attention to the stock based on moves in the options market lately.